| Metric | Q1-26 | Q1-25 |
|---|---|---|
| Revenue | 1,415 | 1,336 |
| Gross Profit | 870.57 | 817.66 |
| Pretax Income | 539.15 | 446.79 |
| Net Income | 418.41 | 348.54 |
| Diluted EPS | 2.92 | 2.37 |
- Net Income YoY
- +20.0%
Key highlights
- Total revenue increased to $1,415 million, up from $1,336 million in the prior year period
- Net income rose to $418.41 million, representing 20.0% growth year-over-year
- Diluted earnings per share reached $2.92 compared to $2.37 in the first quarter of 2025
- Gross profit grew to $870.57 million, reflecting sustained demand for core respiratory products
- Results included a $61.8 million gain recognized from the divestment of subsidiaries
How the Period Went
ResMed's first quarter of fiscal 2026 saw total revenue climb to $1,415 million, a steady increase from the $1,336 million reported in the same period last year. This expansion was primarily fueled by sustained demand for Sleep and Breathing Health products, reflecting broader market growth in medical device availability. The bottom line showed even more pronounced strength, with net income rising 20.0% to $418.41 million, while diluted earnings per share grew to $2.92 from $2.37. This performance underscores a successful start to the fiscal year as the company continues to scale its core respiratory care solutions globally.
Margins and Profitability
Profitability metrics improved during the quarter, with gross profit reaching $870.57 million compared to $817.66 million a year ago. Pretax income saw a sharp jump to $539.15 million from $446.79 million. A major contributor to this bottom-line expansion was a $61.8 million gain recognized from the divestment of certain subsidiaries, which provided a non-recurring boost to the reported net earnings. Despite these exceptional items, ResMed maintained operational efficiency as it managed production costs effectively amidst a complex global supply chain environment for medical electronic components used in its CPAP and ventilation devices.
Business Overview
ResMed Inc. operates as a global leader in the healthcare sector, specifically within the medical instruments and supplies industry. The company specializes in the development, manufacturing, and distribution of medical equipment and cloud-based software applications that diagnose and treat respiratory disorders. Its core business segments are centered on Sleep and Breathing Health, providing continuous positive airway pressure (CPAP) devices, masks, and accessories for patients with sleep apnea and chronic obstructive pulmonary disease (COPD). The firm serves diverse end markets across more than 140 countries, leveraging digital health solutions to improve patient adherence and outcomes.
Financial Context
With a market capitalization of approximately $36.47 billion, ResMed currently trades at a price-to-earnings ratio of 24.24. The stock has experienced a 21.34% price increase over the last quarter, pushing the Relative Strength Index (RSI) to 73.0, which indicates the security is entering overbought territory. Management has reiterated full-year 2027 revenue guidance between $5,750 million and $5,850 million, alongside non-GAAP diluted EPS expected between $12.00 and $12.25. The company's cash flow strategy remains consistent, with a scheduled quarterly cash dividend of $0.66 per share to be paid on December 17, 2026.
Down 5.8% since our story on 30 Oct: $252.83 when we broke it → $238.19 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $239.77 |
|---|---|
| 20 Oct | $245.50 |
| 21 Oct | $246.20 |
| 22 Oct | $253.06 |
| 23 Oct | $252.86 |
| 26 Oct | $253.20 |
| 27 Oct | $250.80 |
| 28 Oct | $250.17 |
| 29 Oct | $252.83 |
| 30 Oct | $229.94 |
| 2 Nov | $232.94 |
| 3 Nov | $227.08 |
| 4 Nov | $240.51 |
| 5 Nov | $239.31 |
| 6 Nov | $235.30 |
| 9 Nov | $235.74 |
| 10 Nov | $234.11 |
| 11 Nov | $238.53 |
| 12 Nov | $238.89 |
| 13 Nov | $239.53 |
| 16 Nov | $238.19 |
Industry Landscape
- The medical device sector continues to benefit from increased global diagnostic rates for sleep-disordered breathing
- Market demand for digital health and remote patient monitoring tools remains a key growth driver for respiratory care providers
- Supply chain stability for medical-grade components has improved significantly compared to previous fiscal years
- Competition remains focused on software integration and patient compliance platforms in the $35 billion global sleep apnea market
- Peer comparisons show ResMed maintaining a leading position in market share for CPAP hardware and masks
| Date | Announcement | Amount |
|---|---|---|
| 29 Oct 2026 | Q1 FY 2027 net revenueSource: stocktitan.net | $1.41 Billion |
| 06 Aug 2026 | Q4 FY 2026 net revenueSource: morningstar.com | $1.46 Billion |
| 30 Apr 2026 | Q3 FY 2026 net revenueSource: SEC filing | $1.43 Billion |
| 29 Jan 2026 | Q2 FY 2026 net revenueSource: listcorp.com | $1.42 Billion |
| 30 Oct 2025 | Q1 FY 2026 net revenueSource: listcorp.com | $1.34 Billion |
| 31 Jul 2025 | Q4 FY 2025 net revenueSource: globenewswire.com | $1.35 Billion |
| Share price | $252.83 |
|---|---|
| Market cap | $36.5B |
| Revenue (annual) | $5.7B |
| P/E (TTM) | 24.2× |
| 1-month price change | +13.46% |
| Sector | HealthcareMedical Instruments & Supplies |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by ResMed Inc. announcing its financial results for the first quarter of fiscal year 2026.
Track RESMED INC live
Get the next RESMED INC SEC filing seconds after it lands.



